Format

Send to

Choose Destination
Cancer Res. 2000 Jan 1;60(1):47-50.

Fumitremorgin C reverses multidrug resistance in cells transfected with the breast cancer resistance protein.

Author information

1
Oncology & Immunoinflammatory Research, Wyeth-Ayerst Research, Pearl River, NY 10965, USA. Rabinds@war.wyeth.com

Abstract

Fumitremorgin C (FTC) is a potent and specific chemosensitizing agent in cell lines selected for resistance to mitoxantrone that do not overexpress P-glycoprotein or multidrug resistance protein. The gene encoding a novel transporter, the breast cancer resistance protein (BCRP), was recently found to be overexpressed in a mitoxantrone-selected human colon cell line, S1-M1-3.2, which was used to identify FTC. Because the drug-selected cell line may contain multiple alterations contributing to the multidrug resistance phenotype, we examined the effect of FTC on MCF-7 cells transfected with the BCRP gene. We report that FTC almost completely reverses resistance mediated by BCRP in vitro and is a pharmacological probe for the expression and molecular action of this transporter.

PMID:
10646850
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center